메뉴 건너뛰기




Volumn 56, Issue 5, 2012, Pages 1006-1011

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Author keywords

HBV genotype; HBV therapy; Immunomodulator; Nucleos(t)ide analogues; Peginterferon; Quantitative HBsAg

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS DNA;

EID: 84859734382     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.12.007     Document Type: Article
Times cited : (151)

References (24)
  • 1
    • 34250011735 scopus 로고    scopus 로고
    • Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients
    • DOI 10.1517/13543784.16.6.777
    • Hadziyannis SJ. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs 2007;16:777-786. (Pubitemid 46882353)
    • (2007) Expert Opinion on Investigational Drugs , vol.16 , Issue.6 , pp. 777-786
    • Hadziyannis, S.J.1
  • 2
    • 66149115173 scopus 로고    scopus 로고
    • Longterm monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
    • Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Longterm monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
    • (2009) Hepatology , vol.49 , pp. 1503-1514
    • Tenney, D.J.1    Rose, R.E.2    Baldick, C.J.3    Pokornowski, K.A.4    Eggers, B.J.5    Fang, J.6
  • 3
    • 78650477355 scopus 로고    scopus 로고
    • Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
    • Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
    • (2011) Gastroenterology , vol.140 , pp. 132-143
    • Heathcote, E.J.1    Marcellin, P.2    Buti, M.3    Gane, E.4    De Man, R.A.5    Krastev, Z.6
  • 5
    • 0033983646 scopus 로고    scopus 로고
    • Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
    • DOI 10.1016/S0168-8278(00)80076-8
    • Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-306. (Pubitemid 30093910)
    • (2000) Journal of Hepatology , vol.32 , Issue.2 , pp. 300-306
    • Santantonio, T.1    Mazzola, M.2    Iacovazzi, T.3    Miglietta, A.4    Guastadisegni, A.5    Pastore, G.6
  • 6
    • 58149316191 scopus 로고    scopus 로고
    • Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
    • Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-295.
    • (2009) J Hepatol , vol.50 , pp. 289-295
    • Shouval, D.1    Lai, C.L.2    Chang, T.T.3    Cheinquer, H.4    Martin, P.5    Carosi, G.6
  • 7
    • 58149296156 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of chronic hepatitis B
    • European Association For The Study Of The Liver
    • European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
    • (2009) J Hepatol , vol.50 , pp. 227-242
  • 8
    • 51049107683 scopus 로고    scopus 로고
    • Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update
    • Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283.
    • (2008) Hepatol Int , vol.2 , pp. 263-283
    • Liaw, Y.F.1    Leung, N.2    Kao, J.H.3    Piratvisuth, T.4    Gane, E.5    Han, K.H.6
  • 9
    • 70349240414 scopus 로고    scopus 로고
    • Chronic hepatitis B: Update 2009
    • Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
    • (2009) Hepatology , vol.50 , pp. 661-662
    • Lok, A.S.1    McMahon, B.J.2
  • 10
    • 40849105240 scopus 로고    scopus 로고
    • Hepatitis B: Reflections on the current approach to antiviral therapy
    • Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48:S2-19.
    • (2008) J Hepatol , vol.48
    • Zoulim, F.1    Perrillo, R.2
  • 12
    • 65449117946 scopus 로고    scopus 로고
    • Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
    • Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-1150.
    • (2009) Hepatology , vol.49 , pp. 1141-1150
    • Brunetto, M.R.1    Moriconi, F.2    Bonino, F.3    Lau, G.K.4    Farci, P.5    Yurdaydin, C.6
  • 13
    • 35948931362 scopus 로고    scopus 로고
    • A pilot study of extended duration peginterferon Alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B
    • DOI 10.1111/j.1572-0241.2007.01449.x
    • Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007;102:2718-2723. (Pubitemid 350179320)
    • (2007) American Journal of Gastroenterology , vol.102 , Issue.12 , pp. 2718-2723
    • Gish, R.G.1    Lau, D.T.-Y.2    Schmid, P.3    Perrillo, R.4
  • 14
    • 65449123444 scopus 로고    scopus 로고
    • Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    • Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-1157.
    • (2009) Hepatology , vol.49 , pp. 1151-1157
    • Moucari, R.1    Mackiewicz, V.2    Lada, O.3    Ripault, M.P.4    Castelnau, C.5    Martinot-Peignoux, M.6
  • 15
    • 77955703978 scopus 로고    scopus 로고
    • Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
    • Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-461.
    • (2010) Hepatology , vol.52 , pp. 454-461
    • Rijckborst, V.1    Hansen, B.E.2    Cakaloglu, Y.3    Ferenci, P.4    Tabak, F.5    Akdogan, M.6
  • 17
    • 77958091146 scopus 로고    scopus 로고
    • Extended (2 years) treatment with peginterferon alfa-2a [40kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B
    • Lampertico P, Vigano M, Di Costanzo G, Sagnelli E, Fasano M, Di Marco V, et al. Extended (2 years) treatment with peginterferon alfa-2a [40kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B. J Hepatol 2010;52:S45.
    • (2010) J Hepatol , vol.52
    • Lampertico, P.1    Vigano, M.2    Di Costanzo, G.3    Sagnelli, E.4    Fasano, M.5    Di Marco, V.6
  • 18
    • 77955383602 scopus 로고    scopus 로고
    • A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B
    • Rijckborst V, Ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010;105:1762-1769.
    • (2010) Am J Gastroenterol , vol.105 , pp. 1762-1769
    • Rijckborst, V.1    Ter Borg, M.J.2    Cakaloglu, Y.3    Ferenci, P.4    Tabak, F.5    Akdogan, M.6
  • 19
    • 66449121130 scopus 로고    scopus 로고
    • Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a
    • Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136 (2169-2179):e2161-2164.
    • (2009) Gastroenterology , vol.136 , Issue.2169-2179
    • Marcellin, P.1    Bonino, F.2    Lau, G.K.3    Farci, P.4    Yurdaydin, C.5    Piratvisuth, T.6
  • 20
    • 77955984417 scopus 로고    scopus 로고
    • Pros and cons of peginterferon versus nucleos (t)ide analogues for treatment of chronic hepatitis B
    • Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos (t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010;9:91-98.
    • (2010) Curr Hepat Rep , vol.9 , pp. 91-98
    • Sonneveld, M.J.1    Janssen, H.L.2
  • 21
    • 73449089431 scopus 로고    scopus 로고
    • Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
    • Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009;14:1183-1188.
    • (2009) Antivir Ther , vol.14 , pp. 1183-1188
    • Moucari, R.1    Martinot-Peignoux, M.2    Mackiewicz, V.3    Boyer, N.4    Ripault, M.P.5    Castelnau, C.6
  • 22
    • 0037381649 scopus 로고    scopus 로고
    • Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy
    • DOI 10.1053/jhep.2003.50148
    • Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-763. (Pubitemid 36397385)
    • (2003) Hepatology , vol.37 , Issue.4 , pp. 756-763
    • Lampertico, P.1    Del, N.E.2    Vigano, M.3    Romeo, R.4    Donato, M.F.5    Sablon, E.6    Morabito, A.7    Colombo, M.8
  • 23
    • 0034802538 scopus 로고    scopus 로고
    • Hepatitis B e antigen-negative chronic hepatitis B
    • DOI 10.1053/jhep.2001.27834
    • Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-624. (Pubitemid 32927983)
    • (2001) Hepatology , vol.34 , Issue.4 I , pp. 617-624
    • Hadziyannis, S.J.1    Vassilopoulos, D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.